The flat revenue and declining Manufacturing segment are headwinds, but the profit turnaround, strong Medical growth, and eyewear divestiture (reducing complexity) are positive. Monitor Q2 for impairment charges from the eyewear transfer and any further restructuring. The buyback provides a floor, but top-line stagnation limits upside without a catalyst.
Price Chart
Executive Summary
Materialise NV reported Q1 2026 results with flat total revenue (€66.3M, -0.2% YoY) but a significant turnaround to net profit of €1.8M from a €0.5M loss a year ago, driven by strong Medical segment growth and improved margins. The company also announced the transfer of its eyewear business to management, retaining a minority stake, with expected Q2 impairment charges. The mixed picture of stagnant top-line but improving profitability and a non-core divestiture warrants a neutral-to-mixed sentiment.
Key Facts
- Q1 2026 total revenue was €66.3M, essentially flat vs. €66.4M in Q1 2025 (-0.2% YoY).
- Net profit swung to €1.8M from a net loss of €0.5M in Q1 2025.
- Medical segment revenue grew 6.7% to €33.2M; Manufacturing segment revenue fell 8.1% to €23.5M.
- Adjusted EBITDA increased 31% to €8.0M from €6.1M; Adjusted EBIT margin improved to 3.7% from 1.0%.
- Company agreed to transfer its eyewear business to management, retaining a minority stake, with expected Q2 2026 impairment charges.
- Share buyback of 511,513 shares for €2.3M completed under the previously announced program.
- Net cash position improved to €72.8M; cash from operations was €6.9M.
Financial Impact
Revenue flat at €66.3M; net profit improved by €2.4M vs. prior-year loss; Adjusted EBITDA up €1.9M to €8.0M.
Risk Factors
- Manufacturing segment revenue declining 8.1% YoY signals ongoing weakness in core 3D printing services.
- Eyewear business transfer may incur material impairment charges in Q2 2026, weighing on near-term earnings.
- Flat total revenue growth suggests limited top-line momentum despite Medical segment strength.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001104659-26-057530 |
| Document: 0001104659-26-057530-index-headers.html | 0001104659-26-057530 |
| Document: 0001104659-26-057530-index.html | 0001104659-26-057530 |
| Document: 0001104659-26-057530.txt | 0001104659-26-057530 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | 6-K | $8.65 | awaiting T+20 | — | $8.73 (+0.92%) |
Oct 19, 2026 7d ago | 6-K | $8.21 | awaiting T+20 | — | $8.73 (+6.33%) |
Oct 13, 2026 13d ago | 6-K | $8.13 | awaiting T+20 | — | $8.73 (+7.38%) |
Oct 5, 2026 21d ago | 6-K | $8.56 | awaiting T+20 | — | $8.73 (+1.99%) |
Sep 8, 2026 6w ago | 6-K | $7.46 $8.50 | ▲ +13.94% | ▲ +11.74% | $8.73 (+17.02%) |
Aug 28, 2026 8w ago | 6-K | $7.21 $8.75 | ▲ +21.36% | ▲ +21.73% | $8.73 (+21.08%) |
Jul 20, 2026 14w ago | 6-K | $6.60 $6.69 | ▲ +1.36% | ▼ −1.20% | $8.73 (+32.27%) |
Jul 13, 2026 15w ago | 6-K | $6.77 $6.87 | ▲ +1.48% | ▼ −1.01% | $8.73 (+28.95%) |
Jul 6, 2026 16w ago | 6-K | $7.04 $6.51 | ▼ −7.53% | ▼ −8.86% | $8.73 (+24.01%) |
Jun 29, 2026 17w ago | 6-K | $7.43 $6.44 | ▼ −13.32% | ▼ −12.30% | $8.73 (+17.50%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers